References
- Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Cana J Cardiol. 2000;16:505–511.
- Panoulas VF, Douglas KMJ, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology. 2008;47(1):72–75. doi:https://doi.org/10.1093/rheumatology/kem311.
- Davis JM 3rd, Maradit KH, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2007;56(3):820–830. doi:https://doi.org/10.1002/art.22418.
- Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–1124. doi:https://doi.org/10.1136/ard.2008.092163.
- Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–770. doi:https://doi.org/10.7326/0003-4819-141-10-200411160-00007.
- Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80:1522–1529. doi:https://doi.org/10.1136/annrheumdis-2021-220577.
- Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449–1455. doi:https://doi.org/10.1002/art.39098.
- Yates W, McCluskey P, Wakefield D. Long-term immunosuppressive therapy for inflammatory eye disease – the link between systemic treatment, cardiovascular risk and disease? Expert Rev Ophthalmol. 2017;12(4):321–330. doi:https://doi.org/10.1080/17469899.2017.1349610.
- Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480. doi:https://doi.org/10.1136/bmj.b2480.
- Udoetuk JD, Dai Y, Ying GS, et al. Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases. Ophthalmology. 2012;119(8):1569–1574. doi:https://doi.org/10.1016/j.ophtha.2012.01.043.
- Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:https://doi.org/10.1056/NEJMoa1509852.
- Rathinam SR, Gonzales JA, Thundikandy R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA. 2019;322(10):936–945. doi:https://doi.org/10.1001/jama.2019.12618.
- Lee JT, Yates WB, Rogers S, Wakefield D, McCluskey P, Lim LL. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol. 2018;102(12):1672–1678. doi:https://doi.org/10.1136/bjophthalmol-2017-311234.
- Wakefield D, McCluskey P, Wildner G, et al. Inflammatory eye disease: pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: recommendations from an expert committee. Autoimmun Rev. 2017;16(3):213–222. doi:https://doi.org/10.1016/j.autrev.2017.01.003.
- Curtis JJ, Galla JH, Woodford SY, Lucas BA, Luke RG. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients. Kidney Int. 1982;22(1):42–47. doi:https://doi.org/10.1038/ki.1982.130.